Why HeraMed (ASX:HMD) and Dimerix (ASX:DXB) are trending?

Summary

  • HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US.
  • Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study.
  • Dimerix is confident that the study will support IND submissions in the UK, Europe, and Canada.

The pandemic has significantly boosted the need for telehealth and remote monitoring needs in the healthcare space. With the surge in demand, the virtual care space too, is witnessing a considerable spurt in activities.

The health crisis has also steered a treatment area that is filling up with clinical trials for drugs indicated for COVID-19 Patients

Today, we will discuss two small-cap healthcare shares that are trending on announcements that look promising for the companies, on the back of opportunities arising from the pandemic.

HeraMED’s Partnership with eCare21

An innovative medical data and technology player HeraMED Limited (ASX:HMD) is a leader in the digital transformation of maternity care. The Company is transforming the prenatal and postpartum experience with its maternity care platform.

On 9 November 2020, HeraMED disclosed that the Company had executed its partnership agreement with eCare21 Inc, a leading provider of virtual care. This partnership agreement enables the HMD’s HeraBEAT device and HeraCARE platform to be offered as part of the eCare21 platform.  

The Company notified that partnership is anticipated to fast-track awareness and take-up of HeraCARE and HeraBEAT across the US.

The key terms of the eCare21 agreement are as follows:

  • Both the Companies to market the HeraCARE platform as a SaaS solution via the platform of eCare21.
  • HeraCARE subscriptions via eCare21 to be offered on similar commercial terms as if offered directly by HMD.
  • Healthcare suppliers to pay an establishment fee and a monthly per-user subscription fee.

The integrated solution which is anticipated to streamline the virtual care deployment for maternal health patients and providers is likely to be available by the 2020 year-end.

HeraMED CEO and Cofounder Mr David Groberman commented-

ALSO READ: COVID-19 may Prove to be Telehealth’s Watershed Moment; Know Why!

On 11 November 2020, the share price of HMD was noted at A$0.120 at AEST 11:46 PM.

Dimerix moves one step closer to COVID-19 trial

Clinical-stage biopharmaceutical player Dimerix Limited (ASX:DXB) is engaged in developing innovative therapies in areas with unmet medical needs for markets across the globe.

On 9 November 2020, Dimerix disclosed that the REMAP-CAP domain protocol including DMX-200 to treat ARDS in COVID-19 patients is available online.  The study domain protocol got published after receiving approval from a 42-member REMAP-CAP International Trial Steering Committee.

The Company disclosed that the protocol will be submitted to regulatory authorities in jurisdictions with high recruitment rates allowing Dimerix to now submit IND to support recruitment of patients to the DMX-200 study arm.

To be included in a global clinical trial of this scale, creates an immense value creation opportunity for Dimerix as well as for its shareholders.

Dimerix has already completed three Phase 2 clinical studies that supported the mechanism of action of DMX-200 in inflammatory processes.  DMX-200 has demonstrated positive efficacy in patients with active inflammatory renal disease.

If DMX-200 demonstrates to be beneficial in COVID-19 associated ARDS, it might show benefit in ARDS linked to other infections too (for example, pneumonia and influenza). Consequently, this provides an opportunity for Dimerix that could expand well beyond the COVID-19 impact.

On 11 November 2020, the share price of DXB was noted at A$0.270  up by 1.9% at AEST 11:53 PM.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK